Exscientia

Exscientia blends advanced AI technology with complex drug discovery to precision-engineer medicines more quickly and efficiently, producing promising compounds that also have a higher likelihood of success. The Oxford-based start-up was the first company to automate drug design and enter an AI-designed molecule into clinical trials after a development phase of under a year. Following its pioneering potential treatment for obsessive compulsive disorder, Exscientia now has a wide-ranging pipeline that includes oncology, inflammatory and auto-immune conditions, psychiatry, and rare diseases.

Venture capital investment enabled Exscientia to expand its AI platform and accelerate its international expansion, notably into the US market. Later funding rounds helped it to move from developing candidates on behalf of partners to building its own extensive proprietary pipeline. The company floated on the Nasdaq in 2021 in an upsized IPO at a valuation of $2.9 billion¹, marking one of the largest floats by a European biotech history.